Safe and rapid outpatient administration of cisplatin ≥ 75 mg/m2 for lung cancer

摘要: 20737 Background: Cisplatin is a standard component of combination chemotherapy for non-small or small-cell lung cancer (NSCLC SCLC), but presents toxic effects, in particular, renal. In most cases, 24-h hydratation recommended to reduce nephrotoxicity after cisplatin administration, requires hospitalization. Thus, quality life patients with short expectancy worsened and cost higher. At our hospital the past 25 years, intermediate high doses are routinely administered well-tolerated. The aim retrospective study was confirm safety this practice an outpatient clinic. Methods: 357 consecutive (median 58 range 25–81) NSCLC SCLC treated at dose ≥ 75 mg/m2 cycles number: 3 (range 1–6) clinic between 2001 2007 were reviewed. Two L G 5% 4 g/L NaCl, 2 g/l KCl, 1 MgCl2 CaCl2 infused 250 ml s...